Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C.
about
Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data.Occult hepatitis C: how convincing are the current data?Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alphaLong-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment.Long-term viral negativity after interferon for chronic hepatitis C virus infection in hemodialysis.Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up.Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more.Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirinHepatocellular carcinoma and hepatitis C in the United States.Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.Liver angiogenesis as a risk factor for hepatocellular carcinoma development in hepatitis C virus cirrhotic patients.Histological outcome of chronic hepatitis B in children treated with interferon alpha.Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C.Antiviral Therapy in Elderly Patients With Hepatitis C Virus InfectionAspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis.Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among NonrespondersChronic hepatitis C in the aged: much ado about nothing or nothing to do?Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis.Hepatitis C Infection in the Elderly.Efficacy and Safety of Sofosbuvir-Based Direct Acting Antivirals for Hepatitis C in Septuagenarians and Octogenarians.Etiological and molecular profile of hepatocellular cancer from India.Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon.Reasons for non-treatment of hepatitis C in veterans in care.Impact of Direct Acting Antiviral Drugs in Treatment Naïve HCV Cirrhosis on Fibrosis and Severity of Liver Disease: A Real Life Experience from a Tertiary Care Center of North IndiaSofosbuvir Based Regimens in the Treatment of Chronic Hepatitis C with Compensated Liver Cirrhosis in Community Care SettingShort-term histological evaluations after achieving a sustained virologic response to direct-acting antiviral treatment for chronic hepatitis C
P2860
Q30892564-85822431-8B2A-4DD3-A892-3E68110651A3Q33395436-1C0CD952-3CAC-4DB5-88EA-E547B386A888Q33867947-9F2F0EE4-1A04-460F-A16A-B4B2E61C8E6AQ33869545-6D679C72-A3C3-4D74-9128-36D8F4A18ACEQ33969758-9AAE840A-A759-4F1A-8228-27F3158322F5Q34125554-5E34181A-B281-429B-8E56-D8CD03AB9E17Q34172595-14C5BA1F-A669-4394-838D-781C98B118CCQ34521418-00FAA224-376B-4ED9-B1F1-4E857C5C3C19Q34528514-6E7CAEAC-BC41-4DCD-8E0F-4EE8036303E5Q35596873-39FB90D7-820B-468C-8504-18AAA1AAB20BQ35615755-DBB6ED09-8D27-4C50-BA36-5BC3B1CE6153Q36496843-3B1A8CB0-FF04-4479-BA06-DCB1EE64CCE1Q36716281-A7A1A057-1829-493D-9E80-FB18D3A18513Q37130025-CFA9DDE1-1F27-4A01-9BDC-8E49C083EA57Q37158382-D87CCA62-4BED-4ADA-8CD8-AE5BE8361AECQ37266324-18A61F91-762A-4F32-8FA7-F195C6B8B1EAQ37641036-843DE93F-5A85-4AB4-9743-A3D7A648D35CQ38198992-D6E1A9BF-F80F-4508-A968-89A4A2817CF4Q38207083-5FE00D87-D408-4C41-A1D5-1B9CD39B186CQ38501726-483937F7-6FC7-4E59-8B6B-128155878E5BQ40140458-1D3351F8-7BA5-489C-9951-69286F8F4562Q42987200-22D37329-9C55-454F-8A31-0E64E104EA49Q42999278-3D2E3F92-1D57-4392-AD69-3DFA61546F55Q43049453-346DD05C-5A93-4D26-BA9E-AFA26E00F350Q45227679-EFE320AA-F9E9-479B-962F-3958DB638B65Q57300681-B6B614E4-AE4C-4711-8E01-9D8189AF3713Q57841253-C2D27BDE-3FC0-4DFA-9E9E-D25DA0004661Q58579652-768EF37D-B088-4011-9736-7CF799DBD2DC
P2860
Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Long-term beneficial effects i ...... erapy for chronic hepatitis C.
@en
Long-term beneficial effects i ...... erapy for chronic hepatitis C.
@nl
type
label
Long-term beneficial effects i ...... erapy for chronic hepatitis C.
@en
Long-term beneficial effects i ...... erapy for chronic hepatitis C.
@nl
prefLabel
Long-term beneficial effects i ...... erapy for chronic hepatitis C.
@en
Long-term beneficial effects i ...... erapy for chronic hepatitis C.
@nl
P2093
P50
P1476
Long-term beneficial effects i ...... erapy for chronic hepatitis C.
@en
P2093
Crosignani A
Maggioni M
Morabito A
Solforosi L
P304
P356
10.1016/S0168-8278(01)00062-9
P577
2001-05-01T00:00:00Z